Obstructive Lung Disease Flashcards

1
Q

What does IL-4 do?

A

directs B lymphocytes to synthesize IgE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What does IL-5 do?

A

regulates eosinophil production and maturation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What does IL-13 do?

A

leads to airway eosinophilia, mucous gland hyperplasia, airway fibrosis and remodeling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the primary T lymphocytes involved in the pathogenesis of asthma?

A

Th2 CD4+ T lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

A 22-year-old male is seen for evaluation of his asthma. He was born at a gestational age of 42 weeks by planned cesarean section to a 19- year-old mother. During pregnancy his mother took herbal pills containing vitamin K. Which of these perinatal factors is associated with the development of childhood asthma?

A

Delivery by cesarean section. Prematurity (birth between 23-27 weeks gestational age), neonatal jaundice, and prenatal exposure to maternal smoking are other risk factors. Maternal age and vitamin K use have not been shown to be risk factors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

There is no gold standard for the diagnosis of asthma. It is a clinical diagnosis based on history, patient characteristics, physical findings, and the results of other evaluations.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

New-onset asthma, although possible, is rare in older adults. The majority of cases are diagnosed in childhood, with most of the remaining cases diagnosed in their teens and twenties.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Baseline spirometry should be obtained in all patients with a suspected diagnosis of asthma.

A

Spirometry can be normal in a patient with asthma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Absolute contraindications to bronchoprovocation testing?

A

SMUK:

Severe airflow limitation (FEV1 < 50% predicted or < 1 L)

Myocardial infarction or stroke in last 3 months

Uncontrolled hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure > 100 mm Hg)

Known aortic aneurysm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

A false positive bronchoprovacation test can occur in patients with?

A

ABCs

Allergic rhinitis Bronchitis
Congestive heart failure, COPD
cystic fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Total serum IgE levels should be measured in patients with moderate-to- severe persistent asthma who are being considered for omalizumab therapy or in patients suspected of having ABPA.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

A 55-year-old patient with asthma had three episodes of fever with worsening dyspnea as well as sputum production with brownish mucus plugs in the last 2 months. Chest radiographs show fleeting infiltrates and an HRCT shows central bronchiectasis. Serum IgE levels are elevated (1200 ng/mL) with peripheral blood eosinophilia (700/mL).
What is the most likely diagnosis? Which test should be done next?

A

Allergic bronchopulmonary aspergillosis.

A skin-prick test checking reactivity to Aspergillus fumigatus should be performed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Medications associated with EGPA:

A

COIL

Cocaine
Omalizumab
Inhaled glucocorticoids Leukotriene-modifying
agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

The most direct way to establish the diagnosis of exercise-induced asthma is via exercise challenge testing.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

In patients with poorly controlled asthma who experience frequent episodes of exercise- induced bronchoconstriction, the most important strategy is to improve overall asthma control.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

In the development of Occupational asthma (OA), the most important factor is the intensity of exposure.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

In a symptomatic patient with ongoing exposure, normal spirometry, and a negative nonspecific bronchoprovocation test excludes the possibility of Occupational asthma.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

The cornerstone of therapy for OA is to avoid further exposure to the sensitizing agent.

A

After complete avoidance of exposure, OA improves gradually then plateaus after about 2 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Reactive airways dysfunction syndrome (RADS) and Irritant Induced Asthma (IrIA) symptoms are not reproduced by inhalation challenge with low levels of offending workplace agents, while symptoms of immunologic OA are reproduced in those conditions.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

After complete cessation of exposure, RADS and IrIA usually improve with time, but some patients continue to have symptoms for at least 1 year and residual physiologic abnormalities like bronchial hyperreactivity can last for several years.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are symptoms that typically begin within 30 minutes to 3 hours following NSAID use:

A

ABCDEF

Asthma-like symptoms (acute asthma exacerbation)

Bronchospasm and laryngospasm (might be severe enough to require intubation)

Congestion and conjunctival redness

Diffuse abdominal cramps (less common)

Epigastric pain (less common) and edema (usually periorbital)
Facial flushing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

The only way to definitively diagnose NSAID sensitivity is via aspirin challenge testing. However, it is rarely used clinically for establishing the diagnosis of AERD. It is mostly performed as a part of a protocol when aspirin desensitization is indicated.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Although other COX-1– inhibiting NSAIDs can be used safely in AERD patients who have been successfully desensitized with aspirin, only subsequent aspirin therapy has been shown to slow the regrowth of nasal polyps and improve asthma symptoms.

A

Successfully desensitized patients should continue taking 325 mg of aspirin or equivalent dose of another COX-1–inhibiting NSAID daily to maintain their desensitized state.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

It is important for patients to understand that medication use is required to control airway inflammation, even in the absence of symptoms.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Never use inhaled long- acting bronchodilators alone in the treatment of asthma. Studies suggest they may increase risk of asthma-related death when not combined with an inhaled corticosteroid.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Anti-IgE therapy is not a first-line therapy for the majority of asthma patients, but it can be considered in patients with atopic asthma refractory to standard therapy.

A

A history of severe and/or frequent exacerbations puts patients at increased risk for experiencing a fatal exacerbation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Epithelial cells –> TGFβ –> small airway fibrosis

A

Macrophages–> LTB4 and IL-8 –> neutrophil and T-cell chemoattractant –> increase d inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are the primary lymphocytes involved in pathogenesis of COPD?

A

A: CD8+ cytotoxic T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

The rate of female deaths from COPD is rising and the deaths per year have exceeded that of men since the year 2000.

A
31
Q

AAT deficiency should be suspected in young (<45 years), white nonsmokers with emphysema and imaging showing bullous disease at the lung bases.

A
32
Q

Digital clubbing is not typical in COPD and may reflect other disease processes such as lung cancer or interstitial lung disease.

A
33
Q

After age 35, nonsmokers can expect to lose up to 30 mL/year in FEV1 while smokers lose close to 60 mL/year.

A

When a smoker stops smoking, the rate of FEV1 loss again approximates that of a nonsmoker.

34
Q

GOLD classification uses three ways to identify high- risk patients when categorizing COPD patients:

A

1) FEV1 < 50% (GOLD III/IV)
2) >2 exacerbations within the previous 12 months
3) one or more hospitalizations for COPD exacerbation.

35
Q

Predictor of survival in COPD:

A

BODE

Body mass index: Lower BMI is a poor prognostic marker

Obstruction (FEV1% predicted)

Dyspnea (mMRC)

Exercise (6-minute
walk distance)

36
Q

A 56-year-old female with COPD describes dyspnea when hurrying on level ground. Post- bronchodilator FEV1 is 45% predicted with no history of exacerbations within the past year. What is the GOLD combined assessment of this patient?

A

She is GOLD III based on her FEV1 and scores 1 on the mMRC without a history of exacerbations.

37
Q

The TORCH trial revealed all the following findings except:
A. Salmeterol reduced exacerbations
B. Salmeterol-fluticasone combination reduced exacerbations
C. Salmeterol-fluticasone combination reduced mortality
D. Pneumonia was more likely in patients taking fluticasone

A

C; salmeterol-fluticasone combination reduced mortality

38
Q

The UPLIFT trial revealed that tiotropium was associated with all the following outcomes except:
A. Reduction in exacerbations
B. Reduction in the rate of FEV1 decline
C. Reduction in hospitalizations related to exacerbations
D. Improved quality of life

A

B; reduction in the rate of FEV1 decline

39
Q

The following inhaled therapies reduce COPD exacerbations: LABA, LAMA, and LABA/ICS

A
40
Q

What therapy has been shown to slow the rate of FEV1 decline?
A. LABA
B. LAMA
C. Smoking cessation
D. LAMA + LABA/ICS E. LAMA + LABA

A

C; smoking cessation

41
Q

Pulmonary rehabilitation improves all of the following except:
A. Dyspnea,
B. Quality of life,
C. FEV1
D. 6-minute walk distance

A

C. FEV1

42
Q

What are the benefits of pulmonary rehabilitation?

A

BREATH(e) EASY

Breathlessness reduction

Recovery after
exacerbation

Exercise capacity (6-
minute walk, shuttle
walk)

Anxiety and depression
reduction

Training of respiratory
muscles

Hospitalization frequency
and days in hospital decreased

Enhanced efficacy of long- acting bronchodilators

Arm function improvement
and endurance training
of upper limbs

Survival (possible mortality
benefit)

Your quality of life
improvement

43
Q

A 55-year-old woman with severe emphysema presents for consultation. FEV1 is 38% predicted, DLCO is 38% predicted, and she is on optimal medical therapy. She has completed pulmonary rehabilitation but still has poor exercise capacity. CT of the chest reveals upper lobe-predominant emphysema. What is the recommended treatment?
A. Bullectomy
B. Lung transplantation C. Hospice care
D. Lung volume reduction surgery (LVRS)

A

D; lung volume reduction surgery (LVRS)

44
Q

A 55-year-old women, a 25-pack-year ex-smoker, presents with dyspnea when walking on level ground after a few minutes. Her post-bronchodilator FEV1/FVC is 0.62. FEV1 is 59% predicted. She has never been treated for a COPD exacerbation. What should be the initial management of her COPD?
A. ICS + LABA
B. LAMA + LABA C. LAMA or LABA +
pulmonary
rehabilitation D. LAMA only

A

C; LAMA or LABA + pulmonary rehabilitation

45
Q

A 67-year-old male sees you for breathlessness when walking at his own pace on level ground. His post-bronchodilator FEV1 percent predicted is 55%. He has been treated for a COPD exacerbation twice within the last year. What GOLD classification is he and what is the recommended initial therapy?

A

GOLD D; ICS + LABA and/or LAMA

46
Q

Inhaled corticosteroids are associated with an increased risk of what?

A

pneumonia in COPD patients.

47
Q

Viral or bacterial respiratory tract infections are the most common cause of COPD exacerbations.

A
48
Q

The single best predictor of a COPD exacerbation is?

A

A history of COPD exacerbations

49
Q

Commercially available genotyping can diagnose 20–30 of the most common mutations, which account for > 90% of the most common mutations of CF

A
50
Q

Infection with B
cepacia complex is considered a contraindication for lung transplant in many centers because of increased mortality.

A

Infection with Burkholderia cepacia complex is considered a contraindication for lung transplant in many centers because of increased mortality

51
Q

What is the most common mutation in CF?

A

ΔF508 mutation, a class II mutation (due to deletion of a single phenylalanine residue at position 508). It is the most common mutation in CF, affecting 70% of CF patients.

52
Q

What gene mutation is targeted by ivacaftor?

A

Ivacaftor, a recently approved CFTR- modulating therapy, targets the G551D CFTR mutation (a class III mutation), found in only about 4% of all CF patients.

53
Q

Order of inhaled medications: bronchodilator → hypertonic saline → dornase alfa → airway clearance → aerosolized antibiotic.

A
54
Q

In patients with CF, chronic infections with what pathogens are associated with accelerated decline in lung functions?

A

P aeruginosa, B cepacia,
and MRSA

55
Q

ICS decreases COPD exacerbation risk: Median exacerbation rate was reduced by 25% was shown by which study?

A

ISOLDE study

56
Q

LAMA decreases exacerbations in COPD shown in which study?
14% reduction in exacerbations, 4 year study

A

UPLIFT study

57
Q

LABA + ICS decreases exacerbations more than ICS or LABA alone shown in which study?

A

TORCH study

58
Q

LAMA decreases exacerbations more than LABA shown in which study?

A

POET-COPD study

59
Q

LAMA/LABA decreases exacerbations more than ICS/LABA shown in which study?

1680 patients followed over 1 year
FEV1 25-60%; mMRC >2; at least 1 exacerbation in the past 1 year

Effect independent of baseline blood eosinophil count

Higher incidence of pneumonia in ICS group

A

FLAME study

60
Q

Triple therapy vs ICS/LABA or LABA/LAMA

52-week trial
8509 patients with mod-very severe COPD
> 1 mod-severe exacerbation in prior year if FEV <50%
> 2 moderate or > 1 severe exacerbation if FEV1 50-65%

A

ETHIOS study

61
Q

Triple therapy vs LAMA/LABA and ICS/LABA
52-week trial
10,355 patients with symptomatic COPD; FEV1 <50% and at least 1 mod-severe
exacerbation in prior year; FEV1 50 -<80% and at least 1 severe or 2 moderate
exac.
shown in which study?

A

IMPACT study

62
Q

Roflumilast and exacerbations in COPD - shows 13% reduction in exacerbations shown in which study?

A

REACT trial

63
Q

When do you use oxygen therapy in stable COPD?

A

Long-term oxygen therapy increases survival in patients with severe chronic resting arterial hypoxemia (PaO2 < 55 mmHg)

PaO2<55mmHgorSaO2<88%

PaO2<59mmHgorSaO2<89%
with:
EKG evidence of cor pulmonale
Hematocrit > 55
Clinical evidence of right heart failure

64
Q

When is surgical lung volume reduction for COPD indicated?

A

survival benefit in upper lobe emphysema/low exercise capacity

65
Q

What does a bullectomy provide?

A

Improves dyspnea, lung function, exercise tolerance

66
Q

When to send a COPD patient for lung transplant evaluation?

A

Suggested criteria: BODE > 7;

FEV1 <15-20%;

> 3 severe exac past year;

1 acute hyercapnic RF;

mod-severe pulmonary hypertension

67
Q

What does a bronchoscopic lung volume reduction do in COPD patients?

A

Improves RV
improves lung function and exercise tolerance

68
Q

What interventions in COPD reduce mortality?

A

LABA+LAMA+ICS
Smoking cessation
Lung volume reduction surgery
Long term O2 therapy
NIPPV
Pulmonary rehab

69
Q

What is the AIR-2 trial and the inclusion criteria?

A

Bronchial thermoplasty - evaluate safety and effectiveness in pts with severe persistent asthma

  • ICS >1000ug BDP equiv + LABA; ± OCS ≤10 mg/day
  • At least 2 symptom days in 4-week baseline
  • Pre-bronchodilator FEV1 ≥ 60% Predicted !!
  • ≤ 8 puffs/24h rescue medication, excluding for exercise
70
Q

What is the AIR-2 trial and the exclusion crtieria?

A

Bronchothermoplasty

Exclusion criteria:
- Post-bronchodilator FEV1 < 65% predicted
- ≥ 3 hospitalizations for asthma exacerbations in past 12 months !!
- > 3 respiratory tract infections in the past 12 months
- ≥ 4 pulses of OCS for asthma in the past 12 months
- Chronic sinus disease defined by 5 or more episodes of sinusitis in the past 12 months or continuous symptoms of sinus infection in last 6 weeks
- Uncontrolled GERD defined by a significant increase in therapy in last 6 weeks
- Known sensitivity to medications required for bronchoscopy (eg. lidocaine, atropine, benzodiazepines)

71
Q

When do you start NIPPV in COPD?

A

PaCO2 >52 mmHg and pH 7.35
Stable COPD
Long term NIPPV targeted to reduce hypercapnia

72
Q

Genetic factor in A1AT deficiency?

A

SERPIN A1 gene mutation

73
Q
A